• Skip to main content
  • Skip to primary sidebar

SpotGamma™

S&P 500 Stock Market Gamma Trading Levels Based on Options Open Interest

  • About
  • Pricing
  • Academy
  • Resources
    • Tool Demos
    • Case Studies
    • Blog
    • Support Center
    • Free Daily Report
    • Free Trading Tools
      • Options Profit Calculator
      • SPX Gamma Exposure
      • Implied Earnings Moves
      • Volatility Ranking
    • Free Training
    • Report Card
  • Login

May 06 2020

Nomura Market Gamma Update 5/6/20

Like we wrote on Twitter and to subscribers a few days ago, the market is stuck in Gamma Neutral and Nomura agrees.

Like our data, Nomura went from ~2940- ~2850. Exact flip points keep flopping. <2800 is trouble | >2900 we can all chase the top | 2800-2900 ¯\_(ツ)_/¯ pic.twitter.com/VvwkBETfms

— spotgamma (@spotgamma) May 4, 2020

Quoted from ZH:

Failing to take advantage of positive dealer gamma, the S&P is now stuck in “no man’s land” and as Nomura’s Charlie McElligott writes in his latest note, the market is “essentially near the Dealer “Neutral Gamma” level (~2845) and between 2 of the 3 largest Gamma strikes on the board (2850 w $1.355B and 2900 with $1.284B), while also now at the “Neutral Delta” level (2882 incl this week’s expiry).

ZH/NOMURA
Nomura SPX SPY Market Gamma May 2020
Nomura SPX SPY Market Gamma May 2020

What this meant then too and occurring simultaneously was a set of further positive inputs into the “vol normalization” process, following the various “short vol” stop-outs in late March—by late April we’d seen the return of Overwriters into “expensive” vols, while too we saw the resumption of an upwardly-sloping front-end of the VIX curve as an “all-clear” signal for the return of systematic “Short Vol” & VIX roll-down strategies

NOMURA

Share This Article

  • Share
  • Twitter
  • LinkedIn
  • Reddit
  • Facebook

Written by SpotGamma · Categorized: Market Analysis · Tagged: gamma neutral, nomura

Don’t have an account with SpotGamma?

Choose the plan you want today to view unique support and resistance levels, access Founder’s Notes and expert commentary, daily trading ranges, and entrance into our private Discord.

 

 

 

Primary Sidebar

Related Resources

  • Options Exchange Monitor — Week of August 15, 2026 (36 SEC notices, 2 CFTC, 0 EDGAR)

    Options Exchange Monitor — Week of August 15, 2026 (36 SEC notices, 2 CFTC, 0 EDGAR)

    August 17, 2026
  • GEX Levels for SPY, QQQ, ES and NQ: Using Index Gamma in Any Product

    GEX Levels for SPY, QQQ, ES and NQ: Using Index Gamma in Any Product

    August 17, 2026
  • How to Trade GEX Levels: A Practical Guide to Gamma-Based Trading

    How to Trade GEX Levels: A Practical Guide to Gamma-Based Trading

    August 17, 2026
  • Free GEX Levels, Charts, and Data: What’s Available and What It’s Actually Worth

    Free GEX Levels, Charts, and Data: What’s Available and What It’s Actually Worth

    August 17, 2026
  • Covered Calls After Assignment: What to Do When the Stock Drops Below Your Cost Basis

    Covered Calls After Assignment: What to Do When the Stock Drops Below Your Cost Basis

    August 17, 2026
  • youtube
  • x
  • Privacy Policy
  • Disclaimer
  • Terms & Conditions
  • Support Center
  • Media
  • Contact Us

©2026 TenTen Capital LLC DBA SpotGamma

All SpotGamma materials, information, and presentations are for educational purposes only and should not be considered specific investment advice nor recommendations. Futures, foreign currency and options trading contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing one's financial security or lifestyle. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. Testimonials appearing on this website may not be representative of other clients or customers and is not a guarantee of future performance or success.

View Full Risk Disclosure